Tvardi Therapeutics, Inc. — Director's Dealing 2023

Jun 27, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Cara Therapeutics, Inc. (CARA)
CIK: 0001346830
Period of Report: 2023-06-23

Reporting Person: Menzaghi Frederique Ph.D. (Chief Scientific Off,SVP-R&D)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-06-23	Common Stock	S	2993	$3.51	Disposed	153747	Direct

Footnotes

F1: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person on September 5, 2018 in accordance with Rule 10b5-1 to satisfy the tax withholding obligations triggered by the vesting of restricted stock units and does not represent a discretionary trade by the Reporting Person.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.51 to $3.52, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.